EP0647134A1 - Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin - Google Patents

Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin

Info

Publication number
EP0647134A1
EP0647134A1 EP93915448A EP93915448A EP0647134A1 EP 0647134 A1 EP0647134 A1 EP 0647134A1 EP 93915448 A EP93915448 A EP 93915448A EP 93915448 A EP93915448 A EP 93915448A EP 0647134 A1 EP0647134 A1 EP 0647134A1
Authority
EP
European Patent Office
Prior art keywords
sibutramine
amount
pharmaceutically acceptable
human
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915448A
Other languages
English (en)
French (fr)
Other versions
EP0647134A4 (de
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0647134A1 publication Critical patent/EP0647134A1/de
Publication of EP0647134A4 publication Critical patent/EP0647134A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention encompasses methods for treating all of the above-described conditions in a human by administering optically pure or substantially optically pure (-) sibutramine to a human in need of such treatment.
  • the present invention encompasses methods for treating the above-described conditions in a human while avoiding the adverse effects associated with the racemic mixture of sibutramine.
  • Mania as well as depression, is characterized by changes in mood as the primary symptom. Either of these two extremes of mood may be accompanied by psychosis with disordered thought and delusional perceptions. Psychosis may have, as a secondary symptom, a change in mood, and it is this overlap with depression that causes much confusion in diagnosis. Severe mood changes without psychosis frequently occur in depression and are often accompanied by anxiety.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or.both, and then, if necessary, shaping the product into the desired presentation.
  • the acute toxicities of the enantiomers of sibutramine and of the racemic mixture thereof are determined in studies in which rats are administered progressively higher doses (mg/kg) of the pure isomers or racemate. That lethal dose which, when administered orally, causes death of 50% of the test animals, is reported as the LD j0 . Comparison of LD J0 values for the enantiomers and racemate provides a measure of the relative toxicity of the compositions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP93915448A 1992-06-23 1993-06-22 Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin. Withdrawn EP0647134A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90304092A 1992-06-23 1992-06-23
US903040 1992-06-23
PCT/US1993/005966 WO1994000114A1 (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Publications (2)

Publication Number Publication Date
EP0647134A1 true EP0647134A1 (de) 1995-04-12
EP0647134A4 EP0647134A4 (de) 1997-07-30

Family

ID=25416838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915448A Withdrawn EP0647134A4 (de) 1992-06-23 1993-06-22 Verfahren und zusammensetzungen zur behandlung von depression und anderen erkrankungen unter verwendung von optisch-reinem sibutramin.

Country Status (5)

Country Link
EP (1) EP0647134A4 (de)
JP (1) JPH08500093A (de)
AU (1) AU4542893A (de)
CA (1) CA2138998A1 (de)
WO (1) WO1994000114A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
CA2366660A1 (en) * 1999-03-19 2000-09-28 Carl M. Mendel Treatment of osteoarthritis
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
EP2319826A1 (de) 2001-02-12 2011-05-11 Wyeth LLC O-Desmethyl-Venlafaxine Succinat Salz
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
CN1671368A (zh) * 2002-07-24 2005-09-21 柏树生物科学公司 疼痛继发性抑郁（dsp）的治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9400114A1 *

Also Published As

Publication number Publication date
CA2138998A1 (en) 1994-01-06
EP0647134A4 (de) 1997-07-30
JPH08500093A (ja) 1996-01-09
AU4542893A (en) 1994-01-24
WO1994000114A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
WO1994000114A1 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
EP0708639A1 (de) Verfahern und zusammensetzungen zur behandlumng von depression und anderen erkrankungen unter verwendung von optisch-reienem sibuttramin
US5648396A (en) Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
RU2001614C1 (ru) R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью
US20020006964A1 (en) Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
EP0687472A2 (de) Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
JP2003521470A (ja) ベンラファキシンの誘導体とその調製および使用方法
EP1904066B1 (de) KOMBINATIONEN VON ESZOPICLON UND TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALINAMIN ZUR BEHANDLUNG DER MENOPAUSE, Perimenopause UND VON KOGNITIVEN STÖRUNGEN
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
CA2318960A1 (en) Pharmaceutical uses of optically pure (+)-bupropion
US20020006963A1 (en) Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
JP2004501130A (ja) ５−ｈｔ３受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての１−アミノ−アルキルシクロヘキサン
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5492933A (en) Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
EP2123642A1 (de) Neues prophylaktisches und/oder therapeutisches mittel gegen neurogene schmerzen
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
US4141993A (en) Compounds of diphenylcyclopentylamine type and methods for their preparation
WO1995010270A1 (en) Method for treating urinary incontinence using optically pure s-terodiline
HK1119078A (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
HK1013797A (en) Potentiation of drug response by a serotonin 1a receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970612

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991118

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEPRACOR INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101